BioInvent International AB (BINV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioInvent International AB (BINV) has a cash flow conversion efficiency ratio of 0.082x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr66.78 Million ≈ $7.19 Million USD) by net assets (Skr810.74 Million ≈ $87.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BINV stock market capitalisation for the company's overall valuation and market capitalisation.
BioInvent International AB - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how BioInvent International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioInvent International AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioInvent International AB ranked by their cash flow conversion efficiency. Explore how high is BioInvent International AB's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D-Link (India) Limited
NSE:DLINKINDIA
|
0.090x |
|
Flutter Entertainment PLC
LSE:FLTR
|
0.034x |
|
Reconnaissance Energy Africa Ltd
V:RECO
|
-0.010x |
|
FIGX Capital Acquisition Corp. Class A Ordinary Share
NASDAQ:FIGX
|
-0.001x |
|
E-Life Mall Corp
TW:6281
|
0.110x |
|
KT Hitel Corporation. Limited
KQ:036030
|
0.052x |
|
Midsona AB (publ)
ST:MSON-B
|
0.016x |
|
Indo Borax & Chemicals Limited
NSE:INDOBORAX
|
0.114x |
Annual Cash Flow Conversion Efficiency for BioInvent International AB (2002–2024)
The table below shows the annual cash flow conversion efficiency of BioInvent International AB from 2002 to 2024. View BioInvent International AB (BINV) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr885.82 Million ≈ $95.33 Million |
Skr-380.47 Million ≈ $-40.94 Million |
-0.430x | -64.64% |
| 2023-12-31 | Skr1.31 Billion ≈ $140.95 Million |
Skr-341.69 Million ≈ $-36.77 Million |
-0.261x | -916.36% |
| 2022-12-31 | Skr1.61 Billion ≈ $172.84 Million |
Skr-41.23 Million ≈ $-4.44 Million |
-0.026x | +85.73% |
| 2021-12-31 | Skr1.37 Billion ≈ $147.11 Million |
Skr-245.84 Million ≈ $-26.46 Million |
-0.180x | -113.52% |
| 2020-12-31 | Skr743.50 Million ≈ $80.01 Million |
Skr-62.62 Million ≈ $-6.74 Million |
-0.084x | +88.62% |
| 2019-12-31 | Skr169.44 Million ≈ $18.23 Million |
Skr-125.43 Million ≈ $-13.50 Million |
-0.740x | +54.13% |
| 2018-12-31 | Skr87.62 Million ≈ $9.43 Million |
Skr-141.39 Million ≈ $-15.22 Million |
-1.614x | -176.96% |
| 2017-12-31 | Skr130.22 Million ≈ $14.01 Million |
Skr-75.88 Million ≈ $-8.17 Million |
-0.583x | -86.35% |
| 2016-12-31 | Skr230.44 Million ≈ $24.80 Million |
Skr-72.05 Million ≈ $-7.75 Million |
-0.313x | +87.31% |
| 2015-12-31 | Skr29.45 Million ≈ $3.17 Million |
Skr-72.57 Million ≈ $-7.81 Million |
-2.464x | -69.91% |
| 2014-12-31 | Skr52.43 Million ≈ $5.64 Million |
Skr-76.03 Million ≈ $-8.18 Million |
-1.450x | -30.04% |
| 2013-12-31 | Skr49.01 Million ≈ $5.27 Million |
Skr-54.65 Million ≈ $-5.88 Million |
-1.115x | +68.83% |
| 2012-12-31 | Skr47.62 Million ≈ $5.13 Million |
Skr-170.38 Million ≈ $-18.34 Million |
-3.578x | -790.00% |
| 2011-12-31 | Skr137.95 Million ≈ $14.85 Million |
Skr-55.45 Million ≈ $-5.97 Million |
-0.402x | +74.66% |
| 2010-12-31 | Skr74.19 Million ≈ $7.98 Million |
Skr-117.70 Million ≈ $-12.67 Million |
-1.586x | +30.58% |
| 2009-12-31 | Skr55.63 Million ≈ $5.99 Million |
Skr-127.14 Million ≈ $-13.68 Million |
-2.285x | -1308.90% |
| 2008-12-31 | Skr231.30 Million ≈ $24.89 Million |
Skr43.73 Million ≈ $4.71 Million |
0.189x | +220.57% |
| 2007-12-31 | Skr214.12 Million ≈ $23.04 Million |
Skr12.63 Million ≈ $1.36 Million |
0.059x | +106.42% |
| 2006-12-31 | Skr110.15 Million ≈ $11.85 Million |
Skr-101.23 Million ≈ $-10.89 Million |
-0.919x | -90.80% |
| 2005-12-31 | Skr219.00 Million ≈ $23.57 Million |
Skr-105.48 Million ≈ $-11.35 Million |
-0.482x | -15.43% |
| 2004-12-31 | Skr212.68 Million ≈ $22.89 Million |
Skr-88.74 Million ≈ $-9.55 Million |
-0.417x | -92.09% |
| 2003-12-31 | Skr304.96 Million ≈ $32.82 Million |
Skr-66.25 Million ≈ $-7.13 Million |
-0.217x | -710.31% |
| 2002-12-31 | Skr394.25 Million ≈ $42.43 Million |
Skr-10.57 Million ≈ $-1.14 Million |
-0.027x | -- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more